Related Experiment Video
Updated: Jul 6, 2025
11:12
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
8.0K
Expression and Localization of Ferritin-Heavy Chain Predicts Recurrence for Breast Cancer Patients with a BRCA1/2
Shuoying Qu1, A Mieke Timmermans1, Bernadette A M Heemskerk-Gerritsen1
1Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Cancers
|January 11, 2024
Summary
Nuclear FTH1 expression is linked to worse survival in BRCA1/2 mutation carriers with breast cancer. This finding highlights a potential prognostic marker but requires further investigation into its underlying mechanisms.
Area of Science:
- Oncology
- Genetics
- Immunology
Background:
- The ferritin heavy chain (FTH1) protein is crucial for iron storage and preventing oxidative DNA damage.
- FTH1 has been identified as a prognostic marker in triple-negative breast cancer, correlating with CD8+ T cell enrichment.
- The prognostic significance of FTH1 expression and localization in other breast cancer subtypes, particularly in BRCA1/2 mutation carriers, remains unexplored.
Purpose of the Study:
- To investigate the association between FTH1 expression, its cellular localization (nuclear vs. cytoplasmic), and survival outcomes in breast cancer patients with BRCA1/2 mutations.
- To explore the relationship between FTH1 expression and the infiltration of specific T cell subsets (CD45+, CD8+, CD4+, FOXP3+) in BRCA1/2-mutated breast cancer.
Main Methods:
- Immunohistochemistry was employed on tissue microarrays from 222 breast cancer patients carrying BRCA1/2 mutations to assess FTH1 expression and localization.
- For a subset of 51 patients, whole slide analysis using automated scoring algorithms was performed to quantify T cell subsets.
- Multivariable analyses were conducted to determine the association between FTH1 expression and disease-free and metastasis-free survival.
Main Results:
- Nuclear FTH1 (nFTH1) expression was significantly associated with shorter disease-free survival (HR=2.71) and metastasis-free survival (HR=3.54) in BRCA1/2 mutation carriers.
- Cytoplasmic FTH1 expression did not show a significant association with survival outcomes in this patient cohort.
- No significant correlation was found between FTH1 expression levels and the abundance of CD45+, CD8+, CD4+, or FOXP3+ immune cells.
Conclusions:
- Nuclear FTH1 expression serves as a potential prognostic indicator for adverse survival outcomes in breast cancer patients with BRCA1/2 mutations.
- The observed association between nFTH1 and poorer survival suggests a role beyond iron storage, potentially involving other cellular pathways.
- Further research is warranted to elucidate the precise mechanisms driving the negative impact of nFTH1 on recurrence-free survival in this specific patient group.
